Compare Eli Lilly And Co (LLY) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Quantum Computing Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Quantum Computing Inc trades at $7.44 (market cap $1.69B). The key difference: Eli Lilly And Co is far larger — about 615.4× Quantum Computing Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Quantum Computing Inc for 25 Days on average.
| LLY | QUBT | |
|---|---|---|
Market Cap | $1.04T | $1.69B |
Volume | 3,064,878 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $1.28K | $21.78 |
52-Week Low | $799.57 | $6.31 |
Typical Hold Time | 93 Days | 25 Days |
Enterprise Value | $1.09T | $753.24M |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
QUBT trades at $7.45, down 2.23% on the day, amid a bearish technical signal from moving averages but with oscillators suggesting potential short-term bullish momentum. The company is in a pre-profitability growth phase, with revenue projected to jump to $10 million in 2026 from $682,000 in 2025, though net losses remain substantial. Recent news highlights the launch of the Dirac-3S quantum system and a $42.5 million backlog, indicating commercial progress but ongoing execution risks.
The investment case hinges on QUBT's ability to scale its quantum computing technology and convert its backlog into sustainable revenue, with a consensus analyst price target of $17.33 implying significant upside. Key risks include persistent cash burn, intense competition, and the speculative nature of the quantum computing sector, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
